93290-12-1

Basic information

• Product Name: ethyl 3-forMyl-4,5-dihydro-1H-pyrazole-5-carboxylate
• Synonyms: ethyl 3-forMyl-4,5-dihydro-1H-pyrazole-5-carboxylate;Ethyl 5-ForMylpyrazole-3-carboxylate;1H-Pyrazole-3-carboxylic acid, 5-forMyl-, ethyl ester;ethyl 5-formyl-1H-pyrazole-3-carboxylate
• CAS NO: 93290-12-1
• Molecular Formula: C₇H₈N₂O₃
• Molecular Weight: 170.1659
• Mol File: 93290-12-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 3-forMyl-4,5-dihydro-1H-pyrazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-forMyl-4,5-dihydro-1H-pyrazole-5-carboxylate(93290-12-1)
• EPA Substance Registry System: ethyl 3-forMyl-4,5-dihydro-1H-pyrazole-5-carboxylate(93290-12-1)

Safety Data

• Hazardous Substances Data: 93290-12-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Ethyl 3-formyl-4,5-dihydro-1H-pyrazole-5-carboxylate is used as a key intermediate in organic synthesis for the creation of various chemical compounds. Its unique structure allows for versatile reactions, facilitating the synthesis of a wide range of organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, ethyl 3-formyl-4,5-dihydro-1H-pyrazole-5-carboxylate is utilized as a building block for the development of new drugs and bioactive molecules. Its reactivity and structural properties make it a promising candidate for the synthesis of pharmaceutical agents with potential therapeutic applications.
Used in Drug Development:
Ethyl 3-formyl-4,5-dihydro-1H-pyrazole-5-carboxylate is employed in drug development as a precursor for the synthesis of novel pharmaceutical agents. Its unique chemical properties contribute to the discovery and creation of innovative drugs with potential therapeutic benefits.
Overall, ethyl 3-formyl-4,5-dihydro-1H-pyrazole-5-carboxylate plays a significant role in the fields of organic chemistry and pharmaceutical development, with its applications spanning across various industries due to its unique structure and reactivity.

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 624-67-9 Propargylic aldehyde 
• 840504-43-0 5-dimethoxymethyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 7664-93-9 sulfuric acid 
• 107-19-7 propargyl alcohol 
• 78-93-3 butanone 
• 623-47-2 propynoic acid ethyl ester 

Downstream Products

• 3112-31-0 3,5-pyrazoledicarboxylic acid 
• 854699-16-4 3-formyl-1H-pyrazole-5-carboxylic acid 

Relevant articles and documents

Stabilization and activation of unstable propynal in the zeolite nanospace and its application to addition reactions

Propynal (HC≡C-CHO), having both a C≡C triple bond and a formyl group in a molecule, is a promising building block but its labile property to easily polymerize often narrows its application for organic synthesis. In a similar way to unstable molecules, such as formaldehyde and acrolein, propynal is also stabilized and remains unchanged in supercages of Na-Y zeolite for over 30 days at ambient temperature. There, the carbonyl oxygen atoms of propynal coordinate to sodium ions in Na-Y which was proved by a 13C-DD/MAS-NMR analysis. In addition, propynal adsorbed in zeolite is sufficiently activated to allow unprecedented reactions; i.e., (1) a 1,3-dipolar cycloaddition with electron-deficient α-diazocarbonyl compounds, (2) a 1,4-addition with mono-, di-, and trimethoxy-substituted benzenes, and (3) a [2 + 2] cycloaddition of unactivated cycloalkenes. The nanospace of the zeolites keeps the products from dimerization during reaction (1) and from successive side-reactions in reaction (2). Quantum chemical calculations demonstrated that reaction (3) proceeds via a one-step-like non-concerted mechanism to afford the corresponding [2 + 2] cycloadducts. These three reactions can produce valuable synthetic intermediates retaining both a formyl group and a C=C double bond.

1,3-dipolar cycloaddition of ethyl diazoacetate to alkynes in the pores of zeolite NaY

Zeolite NaY promotes 1,3-dipolar cycloaddition of ethyl diazoacetate to alkynes having an electron-withdrawing group to afford the corresponding functionalized pyrazoles in high yields. The activation of the dipolarophile inside the pores of NaY is proposed based on the 13CMASNMR analysis. Copyright

1,3-Dipolar cycloaddition in the synthesis of pyrazolyl-substituted nitronyl nitroxides

A new approach to the synthesis of polyfunctional pyrazolyl-substituted nitronyl nitroxides was developed based on the presynthesized pyrazole derivatives prepared by 1,3-dipolar cycloaddition. The structures of the resulting mono- and biradicals were confirmed by X-ray diffraction.

5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES

The present invention relates to certain pyrazole carboxylic acid and ester derivatives, and pharmaceutically acceptable salts thereof, which exhibit useful pharmaceutical properties, for example as agonists for the RUP25 receptor. (I) Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α -glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.the substituents are defined in claim 1.

Substituted pyrazolyl compounds and methods employing such compounds

This invention pertains to novel substituted pyrazolyl compounds useful as intravenous anesthetics represented by the Formula: STR1 including geometric and optically active isomeric forms, and the pharmaceutically acceptable acid addition salts thereof, wherein: one of Y and Z is nitrogen, and the other is CH; R1 is hydrogen or lower-alkyl; R2 and R3 are selected from the group consisting of hydrogen, --CHO, lower-alkylcarbonyl, lower-alkoxy carbonyl, lower-alkylaminocarbonyl, lower-alkyl, lower-alkenyl, lower-alkoxy-lower-alkenyl, lower-alkylcarbonyloxymethyl, substituted and unsubstituted heterocyclic rings, and substituted or unsubstituted aryl groups, wherein the symbol * represents a carbon atom which may be asymmetric and at least one of R2 and R3 is other than hydrogen.